Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
When growth is stimulated in the normally quiescent adult rat liver by partial hepatectomy, steady state levels of messenger RNAs (mRNAs) for c-fos, c-myc, and
p53
increase sequentially during the prereplicative phase which precedes DNA synthesis. Levels of c-fos mRNA are elevated at least 4-fold within 15 min after partial hepatectomy and decrease rapidly by 2 h; c-myc mRNA reaches maximal levels (5-fold over normal) between 30 min and 2 h after the operation. A second, transient phase of expression for both c-fos and c-myc occurs around 8 h after partial hepatectomy.
p53 mRNA
levels increase between 8 and 12 h after the operation (5-fold over normal) and are reflected in an elevation of steady state levels of
p53 protein
between 12 and 15 h after partial hepatectomy. The levels of ras
p21 protein
increase much later at a time of active DNA replication and cell division. Actinomycin D injected at the time of partial hepatectomy blocks the increase in c-myc at 2 h but has no effect on c-fos mRNA levels. Actinomycin D injected at 6 h only partially blocks the increase in c-myc and
p53 mRNA
at 8 h but does not affect c-fos mRNA. Our results suggest that the transient and sequential expression of protooncogenes during the prereplicative stage of liver regeneration is likely to reflect events associated with entry and progression of hepatocytes into the cell cycle and can serve as markers for identifying specific humoral factors involved in liver regeneration.
...
PMID:Sequential protooncogene expression during rat liver regeneration. 351 91
The cdk inhibitor p21WAF1/Cip1 (p21), which can be transcriptionally activated by
p53
, functions to block cell cycle progression. In this study, we analysed the expression of p21 in normal and reactive brain and in gliomas of various malignancy grades. Southern blotting showed no p21 gene deletion. Western blotting and immunohistochemical assay showed that the levels of
p21 protein
in normal and reactive brain tissue were very low; however, p21 was elevated in a majority of gliomas tested, regardless of their malignancy grades. In glioblastoma multiforme, marked elevation of p21 was observed in samples harboring either wild-type or mutant p53. But, in anaplastic astrocytomas, the level of p21 was not elevated in samples harboring mutant-type
p53
. Immunohistochemical staining of paraffin-embedded astrocytomas and glioblastomas showed that tumor cells and not contaminating normal cells were positive for p21. Therefore, overexpression of p21 appears to be an early event in the development of glial neoplasms and
p53
-dependent p21 expression appears to be tumor grade specific.
...
PMID:Increased levels of p21WAF1/Cip1 in human brain tumors. 747 21
The WAF1 gene, located on chromosome 6p, encodes a M(r) 21,000 protein (p21) that can arrest cell growth by associating with and inhibiting cyclin-dependent kinase complexes that are necessary for cells to exit Gr. Transcriptional activation of WAF1 can be accomplished by increasing levels of
p53 protein
induced by various cellular stresses, including DNA damage. Metastatic melanomas are paradoxical in that most overexpress wild-type
p53 protein
, yet cell growth is not inhibited. Thus, it is possible that lack of growth suppression in melanomas is due, in part, to mutations in the WAF1 gene. Therefore, we examined the entire coding region of the WAF1 gene in 24 metastatic melanoma cell lines and three normal melanocyte lines by single-strand conformation polymorphism (SSCP) analysis and direct DNA sequencing. We similarly examined the DNA from lymphoblastoid cell lines, derived from nine individuals belonging to seven melanoma-prone families, in which haplotypes of markers on 6p cosegregate with melanoma for germline mutations in the WAF1 gene. Results indicate that (i) mutation of the WAF1 gene is an infrequent event in individuals with sporadic melanoma or predisposed to familial melanoma and (ii) the uncontrolled growth of melanoma cells is not due to mutation of the WAF1 gene. However, expression studies found a wide variation in the level of
p21 protein
in melanoma cells, suggesting that aberrant regulation of p21 may play a role in melanoma development. Moreover, there was no predictable relationship between p21 expression and
p53
expression, indicating that other,
p53
-independent, pathways may be important for the regulation of p21 in melanoma cells.
...
PMID:Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. 749 59
DNA damage increases
p53 protein
levels and activates transcription of the p21 gene. The
p21 protein
binds to and inhibits cdk2 kinase, causing G1 arrest. Here, we have investigated if a
p53
fusion protein is a substrate for cdk2 kinase in vitro. Cdk2 kinase was immunoprecipitated from NIH3T3 cells and allowed to phosphorylate a human
p53
-GST (glutathione-s-transferase) fusion protein. Cdk2 and cyclin E-cdk2 efficiently phosphorylated both wild-type (wt) and mutant p53-GST. Cdk2 immunoprecipitated from cells in Go and early G1 exhibited minimal
p53
kinase activity, whereas cells in S-phase displayed high levels of
p53
kinase activity. If NIH3T3 cells were X-ray irradiated to induce DNA damage, cdk2
p53
kinase activity was rapidly inhibited within 1 h, but had recovered by 4 h post irradiation. Mutation of serine 315 of
p53
to alanine (
p53
-S315A) abolished phosphorylation by cdk2 kinase. However, wtp53 and
p53
-S315A were equally effective at activating transcription when cotransfected with a
p53
reporter construct. The results demonstrate that ser 315 of
p53
is phosphorylated by cdk2 in vitro. However, ser 315 of wtp53 is not required for transcriptional activity in vivo, suggesting that cdk2 phosphorylation of
p53
may be involved in regulating other cellular functions of wtp53.
...
PMID:Cdk2 kinase phosphorylates serine 315 of human p53 in vitro. 762 34
Programmed cell death (apoptosis) is a normal physiological process, which could in principle be manipulated to play an important role in cancer therapy. The key importance of
p53
expression in the apoptotic response to DNA-damaging agents has been stressed because mutant or deleted
p53
is so common in most kinds of cancer. An important strategy, therefore, is to find ways to induce apoptosis in the absence of wild-type
p53
. In this paper, we compare apoptosis in normal human mammary epithelial cells, in cells immortalized with human papilloma virus (HPV), and in mammary carcinoma cell lines expressing wild-type
p53
, mutant p53, or no
p53 protein
. Apoptosis was induced with mitomycin C (MMC), a DNA cross-linking and damaging agent, or with staurosporine (SSP), a protein kinase inhibitor. The normal and HPV-transfected cells responded more strongly to SSP than did the tumor cells. After exposure to MMC, cells expressing wild-type
p53
underwent extensive apoptosis, whereas cells carrying mutated
p53
responded weakly. Primary breast cancer cell lines null for
p53 protein
were resistant to MMC. In contrast, two HPV immortalized cell lines in which
p53 protein
was destroyed by E6-modulated ubiquitinylation were highly sensitive to apoptosis induced by MMC. Neither
p53 mRNA
nor protein was induced in the HPV immortalized cells after MMC treatment, although
p53 protein
was elevated by MMC in cells with wild-type
p53
. Importantly, MMC induced p21 mRNA but not
p21 protein
expression in the HPV immortalized cells. Thus, HPV 16E6 can sensitize mammary epithelial cells to MMC-induced apoptosis via a
p53
- and p21-independent pathway. We propose that the HPV 16E6 protein modulates ubiquitin-mediated degradation not only of
p53
but also of p21 and perhaps other proteins involved in apoptosis.
...
PMID:The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. 764
The expression level of tumor suppressor
p21 protein
in response to protein kinase inhibitors was examined in MCF-7 cells. Both H7 (serine/threonine kinase inhibitor) and staurosporine (protein kinase C inhibitor) were able to induce
p21 protein
in a time- and dose-dependent manner. Induction of p21 by H7 but not staurosporine required the induction of
p53 protein
. Induction of p21 was preceded by the induction of
p53 protein
. Based on FACS analysis, both H7 and staurosporine act as antimitogenic agents.
...
PMID:Induction of tumor suppressor p21 protein by kinase inhibitors in MCF-7 cells. 767 42
The combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) induces terminal differentiation with an irreversible loss of proliferative capacity in human melanoma cells. Using subtraction hybridization, cDNAs were identified that display enhanced expression in terminally differentiated and growth arrested human melanoma cells (Jiang and Fisher, 1993; Jiang et al., 1994a). A specific melanoma differentiation-associated (mda) cDNA, mda-6, is described whose expression inversely correlates with melanoma progression and growth. mda-6 is identical to WAF1/CIP1/SDI1 that encodes the M(r) 21,000 protein (p21) that is an inhibitor of cyclin-dependent kinases. Actively growing normal melanocyte, SV40-immortalized human melanocyte and dysplastic nevus cell lines synthesize elevated levels of mda-6 mRNA; whereas, actively proliferating radial and early vertical growth phase primary melanomas as well as metastatic human melanoma cells produce reduced levels of mda-6 mRNA. Treatment of primary and metastatic human melanoma cells with IFN-beta + MEZ results in growth inhibition and an increase in mda-6 expression. mda-6 expression also increases when human melanoma cells are grown to high saturation densities or when grown in serum-free medium. Using anti-
p53
and anti-p21 antibodies, an inverse correlation is found between
p53
and
p21 protein
levels during growth arrest and differentiation. Induction of growth arrest and terminal differentiation in H0-1 human melanoma cells by IFN-beta + MEZ results in a temporal decrease in wild-type
p53 protein
levels with a corresponding increase in p21 levels. In the Matrigel-assisted melanoma progression model, mda-6 expression decreases in early vertical growth phase primary human melanoma cells selected for autonomous or enhanced tumor formation in nude mice. In metastatic human melanoma cells displaying a loss of metastatic potential resulting from introduction of a normal human chromosome 6, mda-6 mRNA levels increase. Taken together, these studies indicate that mda-6 (p21) may function as a negative regulator of melanoma growth, progression and metastasis.
...
PMID:The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. 775 61
Expression of p21 has been shown to be up-regulated by the
p53 tumor suppressor
gene in vitro in response to DNA-damaging agents. However, p21 expression can be regulated independently of
p53
, and here we show that expression of p21 in various tissues during development and in the adult mouse occurs in the absence of
p53
function. However, most tissues tested did require
p53
for p21 induction following exposure of the whole animal to gamma irradiation. These results show that normal tissue expression of p21 to high levels is not dependent on
p53
and confirm that induction of p21 by DNA-damaging agents does require
p53
. p21 is expressed upon differentiation of
p53
-deficient murine erythroleukemia (MEL) cells, and the kinetics of induction of p21 in this system suggest that it may be involved in the growth arrest that precedes terminal differentiation. The gene is up-regulated in mouse fibroblasts in response to serum restimulation but the kinetics and levels of induction differ between wild-type and mutant cells. Expression of p21 message following serum restimulation is superinducible by cycloheximide in wild-type but not in
p53
-deficient cells. The increases in p21 mRNA are reflected in changes in
p21 protein
levels. p21 expression also appears to be regulated at the post-transcriptional level because moderate increases in mRNA expression, during differentiation of MEL cells and upon serum restimulation of fibroblasts, are followed by large increases in protein levels. Regulation of the mouse p21 promoter by
p53
depends on two critical
p53
-binding sites located 1.95 and 2.85 kb upstream from the transcriptional initiation site. The sequences mediating serum responsiveness of the promoter map to a region containing the proximal
p53
site.
p53
appears to play a critical role in p21 induction following DNA damage. Moreover, p21 can be regulated independently of
p53
in several situations including during normal tissue development, following serum stimulation, and during cellular differentiation.
...
PMID:p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. 777 11
Terminal differentiation is coupled to withdrawal from the cell cycle. The cyclin-dependent kinase inhibitor (CKI) p21Cip1 is transcriptionally regulated by
p53
and can induce growth arrest. CKIs are therefore potential mediators of developmental control of cell proliferation. The expression pattern of mouse p21 correlated with terminal differentiation of multiple cell lineages including skeletal muscle, cartilage, skin, and nasal epithelium in a
p53
-independent manner. Although the muscle-specific transcription factor MyoD is sufficient to activate p21 expression in 10T1/2 cells, p21 was expressed in myogenic cells of mice lacking the genes encoding MyoD and myogenin, demonstrating that p21 expression does not require these transcription factors. The
p21 protein
may function during development as an inducible growth inhibitor that contributes to cell cycle exit and differentiation.
...
PMID:p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. 786 39
The
p53
tumour-suppressor protein controls the expression of a gene encoding the p21 cyclin-dependent protein kinase (CDK) regulator. Levels of
p21 protein
are increased in senescent cells and p21 overexpression blocks the growth of tumour cells. In normal human cells, but not in many tumour cells, p21 exists in a quaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA). p21 controls CDK activity, thereby affecting cell-cycle control, whereas PCNA functions in both DNA replication and repair. Here we use simian virus 40 DNA replication in vitro to show than p21 directly inhibits PCNA-dependent DNA replication in the absence of a cyclin/CDK. Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase. This regulation results from a direct interaction between p21 and PCNA. Thus, during
p53
-mediated suppression of cell proliferation, p21 and PCNA may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.
...
PMID:The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. 791 Dec 27
1
2
3
4
5
6
7
8
9
10
Next >>